Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling
- PMID: 31001918
- PMCID: PMC11900759
- DOI: 10.1002/kjm2.12073
Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling
Abstract
Ubiquitin specific peptidase 49 (USP49) has been reported as a tumor suppressor in several tumors, but its function and molecular mechanism in non-small cell lung cancer (NSCLC) are still unknown. In this study, USP49 was found downregulated in NSCLC primary tissues and cell lines, and high USP49 predicted a positive index for the overall survival of NSCLC patients. Overexpression of USP49 downregulated the expression levels of Cyclin D1, and upregulated p53 expression. Further flow cytometry analysis showed that overexpressed USP49 induced cell cycle arrest at G0/G1 phase. As a result, overexpression of USP49 significantly inhibited cell growth of NSCLC cells. In mechanism, overexpression of USP49 inhibited PI3K/AKT signaling, but knockdown of USP49 enhanced this signaling. Further studies indicated that USP49 deubiquitinated PTEN and stabilized PTEN protein, which suggested that USP49 inhibited PI3K/AKT signaling by stabilizing PTEN in NSCLC cells. In conclusion, we demonstrated that USP49 was functional in NSCLC cells, and inhibited NSCLC cell growth by suppressing PI3K/AKT signaling, suggesting that USP49 could be as a novel target for NSCLC therapy.
Keywords: AKT; Deubiquitination; PTEN; USP49; non-small cell lung cancer.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.
Conflict of interest statement
All authors declare no conflicts of interests.
Figures




Similar articles
-
Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.Kaohsiung J Med Sci. 2020 Jun;36(6):417-422. doi: 10.1002/kjm2.12194. Epub 2020 Feb 12. Kaohsiung J Med Sci. 2020. PMID: 32052576 Free PMC article.
-
Ubiquitin-specific protease 44 inhibits cell growth by suppressing AKT signaling in non-small cell lung cancer.Kaohsiung J Med Sci. 2019 Sep;35(9):535-541. doi: 10.1002/kjm2.12096. Epub 2019 Jun 14. Kaohsiung J Med Sci. 2019. PMID: 31197957 Free PMC article.
-
MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.Int J Oncol. 2017 Jul;51(1):235-244. doi: 10.3892/ijo.2017.3999. Epub 2017 May 16. Int J Oncol. 2017. PMID: 28534966
-
MicroRNA-4286 promotes cell proliferation, migration, and invasion via PTEN regulation of the PI3K/Akt pathway in non-small cell lung cancer.Cancer Med. 2019 Jul;8(7):3520-3531. doi: 10.1002/cam4.2220. Epub 2019 May 10. Cancer Med. 2019. PMID: 31074594 Free PMC article.
-
PTEN and PI3K/AKT in non-small-cell lung cancer.Pharmacogenomics. 2015 Nov;16(16):1843-62. doi: 10.2217/pgs.15.122. Epub 2015 Nov 10. Pharmacogenomics. 2015. PMID: 26555006 Review.
Cited by
-
PTPLAD2 and USP49 Involved in the Pathogenesis of Smoke-Induced COPD by Integrative Bioinformatics Analysis.Int J Chron Obstruct Pulmon Dis. 2020 Oct 15;15:2515-2526. doi: 10.2147/COPD.S250576. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116468 Free PMC article.
-
RING Finger Protein 38 Mediates LIM Domain Binding 1 Degradation and Regulates Cell Growth in Colorectal Cancer.Onco Targets Ther. 2020 Jan 14;13:371-379. doi: 10.2147/OTT.S234828. eCollection 2020. Onco Targets Ther. 2020. PMID: 32021282 Free PMC article.
-
Long non-coding RNA receptor activator of nuclear factor-κ B ligand promotes cisplatin resistance in non-small cell lung cancer cells.Exp Ther Med. 2021 May;21(5):518. doi: 10.3892/etm.2021.9949. Epub 2021 Mar 22. Exp Ther Med. 2021. Retraction in: Exp Ther Med. 2024 May 01;28(1):272. doi: 10.3892/etm.2024.12560. PMID: 33815591 Free PMC article. Retracted.
-
Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma.Cell Biosci. 2022 May 3;12(1):53. doi: 10.1186/s13578-022-00791-w. Cell Biosci. 2022. PMID: 35505371 Free PMC article.
-
Advances in deubiquitinating enzymes in lung adenocarcinoma.J Cancer. 2021 Jul 25;12(18):5573-5582. doi: 10.7150/jca.56532. eCollection 2021. J Cancer. 2021. PMID: 34405018 Free PMC article. Review.
References
-
- Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954–5958. - PubMed
-
- Patel JD, Paz‐Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. Pemetrexed continuation maintenance phase 3 trials in nonsquamous, non‐small‐cell lung cancer: Focus on 2‐year overall survival and continuum of care. Clin Lung Cancer. 2018;19:e823–e830. - PubMed
-
- Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, et al. Mechanism and non‐mechanism based imaging biomarkers for assessing biological response to treatment in non‐small cell lung cancer. Eur J Cancer. 2016;59:65–78. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous